Clinical trials: Metformin, completed
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Obesity, Overweight
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
- Trial name
- NCT06605703
- Testing
- WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- WW International Inc
Diabetes Mellitus, Lactic Acidosis
Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
The purpose of this study is to determine whether metformin causes lactic acidosis in diabetic patients with preserved kidney function, undergoing coronary angiography or angioplasty with new contrast media.
- Trial name
- NCT01873859
- Testing
- Metformin
- Where
- Iran
- Volunteers
- 166 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi
Healthy Subjects in Fasted and Fed State
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.
- Trial name
- NCT03216278
- Testing
- Dapagliflozin/metformin XR 5/500mg, Dapagliflozin/metformin XR 5/500 mg, Dapagliflozin/metformin XR 10/1000mg
- Where
- Brazil
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Dyslipidemia
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
- Trial name
- NCT00490178
- Testing
- Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Solvay Pharmaceuticals
Healthy
Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)
Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to determine the bioequivalence of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck…
- Trial name
- NCT05798715
- Testing
- Gleptomet 50/1000(Metformin HCl & Sitagliptin), Janumet 50/1000(Metformin HCl & Sitagliptin)
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Polycystic Ovarian Syndrome
Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Objective: 1. To investigate the changes in the levels of interleukin-6 and interleukin-8 after 3 months treatment with metformin alone and combination of metformin and pioglitazone in patients with polycystic ovarian syndrome…
- Trial name
- NCT03117517
- Testing
- Metformin, Metformin, Pioglitazone
- Where
- Pakistan
- Volunteers
- 106 people
- Sponsor
- Khyber Medical University Peshawar
Type 2 Diabetes
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to…
- Trial name
- LixiLan-O (NCT02058147)
- Testing
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 273 sites in United States, Australia and 21 more
- Volunteers
- 1,170 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Polycystic Ovary Syndrome, Obesity
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.
- Trial name
- NCT02909933
- Testing
- liraglutide, metformin and liraglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Type 2 Diabetes
Metformin in Women With Type 2 Diabetes in Pregnancy Trial
Insulin is the standard treatment for the management of type 2 diabetes in pregnancy, however despite treatment with insulin, these women continue to face increased rates of adverse maternal and fetal outcomes.
- Trial name
- MiTy (NCT01353391)
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Mount Sinai Hospital, Canada
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at…
- Trial name
- NCT01579812
- Testing
- Metformin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diabetes Mellitus, Type 2
Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics
Metformin is a biguanide that is marketed as an oral anti-diabetic drug. Metformin treatment in concert with diet and exercise is the consensus first-line treatment for type 2 diabetes mellitus (T2DM), and therefore it will…
- Trial name
- NCT01357876
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer
Prostate cancer is the second leading cause of mortality in men, representing 10 deaths about of 100 cancers (INVS 2009). Treatment for metastatic prostate cancer, when becoming resistant to hormone-treatment, is mostly resumed…
- Trial name
- TAXOMET (NCT01796028)
- Testing
- METFORMIN, TAXOTERE®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Antoine Lacassagne
Long COVID-19 Syndrome, Chronic Fatigue Syndrome
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that…
- Trial name
- REVIVE (NCT06128967)
- Testing
- Fluvoxamine Maleate 100 MG, Metformin Extended Release Oral Tablet
- Where
- 6 sites in Brazil
- Volunteers
- 399 people
- Sponsor
- Cardresearch
Diabetes Mellitus, Type 2, Medication Adherence
The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
A 4 week prospective, randomized controlled study was carried out to assess the impact of a care delivery intervention which focused on blood glucose (BG) management among adults with type 2 diabetes presenting to the Emergency…
- Conditions
- Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA
- Trial name
- STEP-DM (NCT02269098)
- Testing
- Diabetes medication management
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Medstar Health Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.